L-NGC-5HT2 (ATCC® CRL-10287)

Organism: Mus musculus, mouse  /  Cell Type: fibroblast  /  Tissue: subcutaneous connective tissue; areolar and adipose  / 

Organism Mus musculus, mouse
Tissue subcutaneous connective tissue; areolar and adipose
Cell Type fibroblast
Product Format frozen
Morphology fibroblast
Culture Properties adherent
Biosafety Level 1 (SV-40 Transformed African Green Monkey)

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Strain C3H/An
Storage Conditions liquid nitrogen vapor phase
Derivation
This line is a derivative of L-M(TK-) that is stably transfected with the gene for the human type 2 5-hydroxytryptamine (serotonin) receptor (5HT2).
Receptor Expression
5-hydroxytryptamine (serotonin, 5HT2), expressed
Comments
This line is a derivative of L-M(TK-) that is stably transfected with the gene for the human type 2 5-hydroxytryptamine (serotonin) receptor (5HT2).
Complete Growth Medium Dulbecco's modified Eagle's medium with 4.5g/L glucose, 90%; fetal bovine serum, 10%
Subculturing
Protocol: Remove medium, add fresh 0.25% trypsin solution for 2 to 5 minutes, remove trypsin and let the culture sit at 37C for 10 to 15 minutes. Add fresh medium, aspirate and dispense into new flasks.
Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:8 is recommended
Medium Renewal: 2 to 3 times per week
Cryopreservation
Freeze medium: culture medium, 90%; DMSO, 10%
Storage temperature: liquid nitrogen vapor phase
Name of Depositor Synaptic Pharmaceutical Corporation
U.S. Patent Number
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished.
References

Gluchowski C, et al. Use of alpha1C specific compounds to treat benign prostatic hyperplasia. US Patent 5,403,847 dated Apr 4 1995

Basic Documentation
References

Gluchowski C, et al. Use of alpha1C specific compounds to treat benign prostatic hyperplasia. US Patent 5,403,847 dated Apr 4 1995